Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Abiomed Lands China Approval for Cardiac Device

publication date: Feb 3, 2014
Abiomed has been granted China approval for two versions of its minimally invasive heart pump, the Impella 2.5 and Impella 5.0. Abiomed is a Massachusetts-based market of cardiac devices. The Impellas, which are designed to provide temporary assistance to the heart, are inserted into the left ventricle via a catheter and pump blood into the aorta. The devices are used as temporary support for patients who are otherwise too weak to undergo an interventional cardiac procedure. More details....

Stock Symbol: (NSDQ: ABMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital